{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:38:58Z","timestamp":1770435538096,"version":"3.49.0"},"reference-count":72,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1097\/ftd.0b013e31826a6306","type":"journal-article","created":{"date-parts":[[2012,11,3]],"date-time":"2012-11-03T09:25:24Z","timestamp":1351934724000},"page":"622-628","source":"Crossref","is-referenced-by-count":26,"title":["Old and New Antirheumatic Drugs and the Risk of Hepatotoxicity"],"prefix":"10.1097","volume":"34","author":[{"given":"Maria Grazia","family":"Anelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crescenzio","family":"Scioscia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignazio","family":"Grattagliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Lapadula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210129","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.3748\/wjg.15.4865","article-title":". Biochemical mechanisms in drug-induced liver injury: certainties and doubts.","volume":"15","author":"Grattagliano","year":"2009","journal-title":"World J Gastroenterol"},{"key":"R2-3-20210129","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1006\/rtph.2000.1399","article-title":". Concordance of the toxicity of pharmaceuticals in humans and in animals.","volume":"32","author":"Olson","year":"2000","journal-title":"Regul Toxicol Pharmacol"},{"key":"R3-3-20210129","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ajg.2008.149","article-title":". How common is diclofenac-associated liver injury Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.","volume":"104","author":"Laine","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R4-3-20210129","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/pds.1351","article-title":". Hospitalisations and emergency department visits due to drug-drug interactions: a literature review.","volume":"16","author":"Becker","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R5-3-20210129","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1001\/jama.289.13.1652","article-title":". Drug-drug interactions among elderly patients hospitalized for drug toxicity.","volume":"289","author":"Juurlink","year":"2003","journal-title":"JAMA"},{"key":"R6-3-20210129","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00002512-200825040-00007","article-title":". Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance.","volume":"25","author":"Tulner","year":"2008","journal-title":"Drugs Aging"},{"key":"R7-3-20210129","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.2174\/092986709788803097","article-title":"Current concepts of mechanisms in drug-induced hepatotoxicity.","volume":"16","author":"Russmann","year":"2009","journal-title":"Curr Med Chem"},{"key":"R8-3-20210129","first-page":"322","article-title":". Avoiding drug interactions: heres help.","volume":"59","author":"Grattagliano","year":"2010","journal-title":"J Fam Pract"},{"key":"R9-3-20210129","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/bmj.332.7539.488-a","article-title":"Case reports of suspected adverse drug reactions: case reports generate signals efficiently.","volume":"332","author":"Russmann","year":"2006","journal-title":"BMJ"},{"key":"R10-3-20210129","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.cld.2007.06.004","article-title":"Nonsteroidal anti-inflammatory drug-induced hepatotoxicity.","volume":"11","author":"Aithal","year":"2007","journal-title":"Clin Liver Dis"},{"key":"R11-3-20210129","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrrheum.2010.214","article-title":"Hepatotoxicity related to antirheumatic drugs.","volume":"7","author":"Aithal","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"R12-3-20210129","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/pds.755","article-title":". Prescription and non-prescription analgesic use among the US adult population: results from the third National Health and Nutrition Examination Survey (NHANES III).","volume":"12","author":"Paulose-Ram","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R13-3-20210129","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2125.2004.02133.x","article-title":". Acute and clinically relevant drug-induced liver injury: a population based case-control study.","volume":"58","author":"de Abajo","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"R14-3-20210129","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/bmj.327.7405.18","article-title":". Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs.","volume":"327","author":"Traversa","year":"2003","journal-title":"BMJ"},{"key":"R15-3-20210129","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/hep.20800","article-title":"Outcome and prognostic markers in severe drug-induced liver disease.","volume":"42","author":"Bjornsson","year":"2005","journal-title":"Hepatology"},{"key":"R16-3-20210129","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2036.2004.02092.x","article-title":"Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs.","volume":"20","author":"Rubenstein","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R17-3-20210129","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00001648-199311000-00004","article-title":"The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs.","volume":"4","author":"Perez","year":"1993","journal-title":"Epidemiology"},{"key":"R18-3-20210129","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1517\/14740338.3.6.519","article-title":"Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity.","volume":"3","author":"Aithal","year":"2004","journal-title":"Expert Opin Drug Saf"},{"key":"R19-3-20210129","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/hep.1840220320","article-title":". Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions.","volume":"22","author":"Banks","year":"1995","journal-title":"Hepatology"},{"key":"R20-3-20210129","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep.20205","article-title":". Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity.","volume":"39","author":"Aithal","year":"2004","journal-title":"Hepatology"},{"key":"R21-3-20210129","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1021\/tx970203+","article-title":". Selective protein adduct formation of diclofenac glucuronide is critically dependent on the rat canalicular conjugate export pump (Mrp2).","volume":"11","author":"Seitz","year":"1998","journal-title":"Chem Res Toxicol"},{"key":"R22-3-20210129","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/0008-5472.CAN-05-2857","article-title":". Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone.","volume":"66","author":"Thibaudeau","year":"2006","journal-title":"Cancer Res"},{"key":"R23-3-20210129","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.gastro.2006.11.023","article-title":". Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes.","volume":"132","author":"Daly","year":"2007","journal-title":"Gastroenterology"},{"key":"R24-3-20210129","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1365-2133.2003.05321.x","article-title":". Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.","volume":"148","author":"Ohtani","year":"2003","journal-title":"Br J Dermatol"},{"key":"R25-3-20210129","first-page":"724","article-title":". Prospective study of the association between NAT2 gene haplotypes and severe adverse events with sulfasalazine therapy in patients with rheumatoid arthritis.","volume":"35","author":"Soejima","year":"2008","journal-title":"J Rheumatol"},{"key":"R26-3-20210129","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1471-2474-9-48","article-title":". Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: a case series from a local surveillance of serious adverse events.","volume":"9","author":"Jobanputra","year":"2008","journal-title":"BMC Musculoskelet Disord"},{"key":"R27-3-20210129","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1085-5629(96)80038-1","article-title":"Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS).","volume":"15","author":"Bocquet","year":"1996","journal-title":"Semin Cutan Med Surg"},{"key":"R28-3-20210129","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/rheumatology\/39.6.655","article-title":". A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.","volume":"39","author":"Emery","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"R29-3-20210129","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2165\/11316650-000000000-00000","article-title":"Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing.","volume":"32","author":"Alcorn","year":"2009","journal-title":"Drug Saf"},{"key":"R30-3-20210129","first-page":"472","article-title":"Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugscomparison of drugs and adverse reactions.","volume":"35","author":"Helliwell","year":"2008","journal-title":"J Rheumatol"},{"key":"R31-3-20210129","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.49.1.25","article-title":". Azathioprine induced fever, chills, rash, and hepatotoxicity in rheumatoid arthritis.","volume":"49","author":"Jeurissen","year":"1990","journal-title":"Ann Rheum Dis"},{"key":"R32-3-20210129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0168-8278(97)82330-6","article-title":"Vanishing bile duct syndrome in drug-induced liver disease.","volume":"26","author":"Desmet","year":"1997","journal-title":"J Hepatol"},{"key":"R33-3-20210129","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1053\/gast.2002.32420","article-title":". 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.","volume":"122","author":"Dubinsky","year":"2002","journal-title":"Gastroenterology"},{"key":"R34-3-20210129","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1365-2036.2008.03782.x","article-title":". Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease.","volume":"28","author":"Ansari","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"R35-3-20210129","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/ard.2002.001826","article-title":"Hepatic manifestations of autoimmune rheumatic diseases.","volume":"63","author":"Abraham","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"R36-3-20210129","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/00042737-200605000-00018","article-title":". Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy.","volume":"18","author":"Seiderer","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R37-3-20210129","first-page":"469","article-title":"Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort.","volume":"35","author":"Chandran","year":"2008","journal-title":"J Rheumatol"},{"key":"R38-3-20210129","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/ard.2008.094474","article-title":". Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative.","volume":"68","author":"Visser","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R39-3-20210129","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/rheumatology\/36.3.338","article-title":". Quantitative liver function in patients with rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study.","volume":"36","author":"Beyeler","year":"1997","journal-title":"Br J Rheumatol"},{"key":"R40-3-20210129","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/ard.2008.093690","article-title":"Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research.","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R41-3-20210129","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1136\/ard.2009.112136","article-title":". Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis.","volume":"69","author":"Sokolove","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R42-3-20210129","first-page":"1454","article-title":". Drug use and toxicity in psoriatic disease: focus on methotrexate.","volume":"35","author":"Taylor","year":"2008","journal-title":"J Rheumatol"},{"key":"R43-3-20210129","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","article-title":". Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.","volume":"144","author":"Kremer","year":"2006","journal-title":"Ann Intern Med"},{"key":"R44-3-20210129","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2165\/00003495-200262040-00005","article-title":". Drugs affecting homocysteine metabolism: impact on cardiovascular risk.","volume":"62","author":"DeSouza","year":"2002","journal-title":"Drugs"},{"key":"R45-3-20210129","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/hep.20708","article-title":"Homocysteine, the bad thiol.","volume":"41","author":"Mato","year":"2005","journal-title":"Hepatology"},{"key":"R46-3-20210129","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2217\/pgs.09.139","article-title":". Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis.","volume":"11","author":"Kooloos","year":"2010","journal-title":"Pharmacogenomics"},{"key":"R47-3-20210129","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3899\/jrheum.080576","article-title":"Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity.","volume":"36","author":"Fisher","year":"2009","journal-title":"J Rheumatol"},{"key":"R48-3-20210129","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jhep.2009.06.008","article-title":". Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis.","volume":"51","author":"Miele","year":"2009","journal-title":"J Hepatol"},{"key":"R49-3-20210129","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jhep.2007.01.024","article-title":". Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment.","volume":"46","author":"Rosenberg","year":"2007","journal-title":"J Hepatol"},{"key":"R51-3-20210129","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.amjmed.2004.02.032","article-title":". Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis.","volume":"117","author":"Suissa","year":"2004","journal-title":"Am J Med"},{"key":"R52-3-20210129","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nrd2196","article-title":"Biologic therapies in rheumatology: lessons learned, future directions.","volume":"6","author":"Strand","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"R53-3-20210129","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11739-009-0342-4","article-title":". Infliximab-related hepatitis: discussion of a case and review of the literature.","volume":"5","author":"Mancini","year":"2010","journal-title":"Intern Emerg Med"},{"key":"R54-3-20210129","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/rheumatology\/ker190","article-title":". Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review.","volume":"50","author":"Brunasso","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"R55-3-20210129","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1517\/14728222.11.5.613","article-title":". The IL-6sIL-6R complex as a novel target for therapeutic approaches.","volume":"11","author":"Rose-John","year":"2007","journal-title":"Expert Opin Ther Targets"},{"key":"R56-3-20210129","doi-asserted-by":"crossref","first-page":"i2","DOI":"10.1136\/ard.2010.146852","article-title":". Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010.","volume":"70","author":"Furst","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R57-3-20210129","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2147\/IJGM.S23920","article-title":". Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports.","volume":"4","author":"Mahamid","year":"2011","journal-title":"Int J Gen Med"},{"key":"R58-3-20210129","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","article-title":". Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.","volume":"70","author":"Buch","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R59-3-20210129","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2010.30.0673","article-title":". American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases.","volume":"28","author":"Artz","year":"2010","journal-title":"J Clin Oncol"},{"key":"R60-3-20210129","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00296-009-1202-2","article-title":". Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis.","volume":"31","author":"Pyrpasopoulou","year":"2011","journal-title":"Rheumatol Int"},{"key":"R61-3-20210129","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood-2009-10-245878","article-title":". Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study.","volume":"116","author":"Dammacco","year":"2010","journal-title":"Blood"},{"key":"R62-3-20210129","first-page":"4695","article-title":"Terui Y, et al..","volume":"26","author":"Ennishi","year":"2008","journal-title":"Does rituximab really induce hepatitis C virus reactivation J Clin Oncol"},{"key":"R63-3-20210129","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/hep.510260319","article-title":"Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis.","volume":"26","author":"Maria","year":"1997","journal-title":"Hepatology"},{"key":"R64-3-20210129","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/pds.1207","article-title":"A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience.","volume":"15","author":"Goldkind","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R65-3-20210129","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1023\/A:1007649815992","article-title":". Hepatotoxicity due to mitochondrial dysfunction.","volume":"15","author":"Pessayre","year":"1999","journal-title":"Cell Biol Toxicol"},{"key":"R66-3-20210129","first-page":"378","article-title":". Noninvasive assessment of the effect of xenobiotics on mitochondrial function in human beings: studies with acetylsalicylic acid and ethanol with the use of the carbon 13-labeled ketoisocaproate breath test.","volume":"125","author":"Lauterburg","year":"1995","journal-title":"J Lab Clin Med"},{"key":"R67-3-20210129","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jhep.2010.04.043","article-title":". Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study.","volume":"53","author":"Laharie","year":"2010","journal-title":"J Hepatol"},{"key":"R68-3-20210129","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.medcli.2010.12.024","article-title":". Evaluation of liver fibrosis by transient elastography in methotrexate treated patients.","volume":"137","author":"Barbero-Villares","year":"2011","journal-title":"Med Clin (Barc)"},{"key":"R69-3-20210129","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","article-title":"Guidelines: management of chronic hepatitis B.","volume":"50","year":"2009","journal-title":"J Hepatol"},{"key":"R70-3-20210129","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/ng0810-650","article-title":"Preempting and preventing drug-induced liver injury.","volume":"42","author":"Aithal","year":"2010","journal-title":"Nat Genet"},{"key":"R71-3-20210129","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/MD.0b013e3182380a76","article-title":". Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases.","volume":"90","author":"Perez-Alvarez","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"R72-3-20210129","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1365-2141.2006.06465.x","article-title":"Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies.","volume":"136","author":"Lalazar","year":"2007","journal-title":"Br J Haematol"},{"key":"R73-3-20210129","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.cgh.2006.05.027","article-title":"Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention.","volume":"4","author":"Mindikoglu","year":"2006","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e31826a6306","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:40:03Z","timestamp":1620952803000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201212000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":72,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e31826a6306","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}